trial

Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics

NCTId NCT03790345
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 45 (estimated)
Sponsored by Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Primary completion 2020-06-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
45 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-09-03
Primary completion
2020-06-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
PyridoxineCobalamin

Sponsors

Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do CearaLead Sponsor

Investigators

1
Lia LO Sanders, MD, PhDPrincipal Investigator

Sites

1 total
Fortaleza, Brazil

Linked catalysts

1
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychot — primary completion2020-06-03

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE2,PHASE3
Primary Completion Date
2020-06-03
Status
UNKNOWN
relationships
The graph out of here
drug
Pyridoxine
drug
Cobalamin
drug
lead_sponsor
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
company
indication
Schizophrenia
indication
Schizophrenia
indication
Drug Induced Movement Disorder, Unspecified
indication
investigator
Lia LO Sanders, MD, PhD
person